clinical trial · NCT05263934
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
GlaxoSmithKline·phase3·active not recruiting·n = 163
Eosinophilic Granulomatosis With PolyangiitisDepemokimabMepolizumabPlacebo matching mepolizumabPlacebo matching depemokimab
brief summary
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
started
Jul 14, 2022
primary completion
Sep 29, 2026
completion
Oct 27, 2026
last updated
Nov 20, 2025
official title
A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol